Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Ionis Pharmaceuticals

Founders Christopher K. Mirabelli Daniel Ripley

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 5
Average round size
info
The average size of a deal this fund participated in
$38M
Portfolio companies 5
Rounds per year 0.15
Lead investments 2
Exits 1
Key employees Soon

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Therapeutics
  • Medical
  • Health Care

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Ionis Pharmaceuticals:
Typical Co-investors
Ionis Pharmaceuticals is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Ionis Pharmaceuticals:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Bleu Capital New York, New York, United States
Bloomsbury Bioseed Fund England, London, United Kingdom
C.Domain Capital Beijing, Beijing, China
China Literature Beijing, Beijing, China
Crohn's & Colitis Foundation of America Hatfield, Hertfordshireshire, United Kingdom
DNB Norway, Oslo
Fuhai Yintao China, Guangdong, Shenzhen
FUJIFILM Chiyoda, Japan
HB Realty Investments, Inc. -
Investitions- und Strukturbank Rheinland-Pfalz Germany, Mainz, Rheinland-Pfalz
Jiaxing Pucheng Gquan Touzi Hehuoqiye China, Jiaxing, Zhejiang
Marubeni America Corporation New York, New York, United States
Norwegian Research Council Norway, Oslo
Proto Accelerator Lansing, Michigan, United States
Shefa Capital Israel, Tel Aviv, Tel Aviv District
Taihe Entertainment Group Beijing, Beijing, China
TechMinsk Belarus, Minsk
Valquest Partners Beirut, Beyrouth, Lebanon
Viva BioInnovator China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Aro Biotherapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$88M05 Jan 2021 Philadelphia, Pennsylvania, United States

Empirico

Biotechnology
Medical
$17M09 Jan 2020 San Diego, California, United States

Atlantic Healthcare

Biotechnology
Health Care
Pharmaceutical
$6M01 Mar 2007 Uttlesford, England, United Kingdom

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Ionis Pharmaceuticals?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 5
Average round size 38M
Rounds per year 0.15
Peak activity year 2021
Lead investments 2
Exits 1
Group Appearance index 0.60

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Aro Biotherapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$88M05 Jan 2021 Philadelphia, Pennsylvania, United States

Empirico

Biotechnology
Medical
$17M09 Jan 2020 San Diego, California, United States

Atlantic Healthcare

Biotechnology
Health Care
Pharmaceutical
$6M01 Mar 2007 Uttlesford, England, United Kingdom
Crunchbase icon

Content report

The following text will be sent to our editors: